Poltreg (PTG) Q3 2024 earnings summary

Executive summary

• Focus on developing innovative TREG cell therapies for autoimmune diseases, with advanced clinical programs in type 1 diabetes and multiple sclerosis.

• Maintains a diversified R&D pipeline, including next-generation TREGs (CAR-TREG, TCR-TREG) and ongoing international collaborations.

• Key strategic goals include partnering with major pharma, expanding clinical trials, and commercializing therapies.

Financial highlights

• Revenue for the first nine months of 2024 was 350k PLN, down from 1.2m PLN year-over-year, mainly due to technology transfer and certification of the new manufacturing facility.

• Net loss for the period was 14.2m PLN, compared to 9.4m PLN in the same period last year.

• Operating expenses increased to 17.6m PLN from 15.7m PLN year-over-year, driven by higher amortization and material costs.

• Cash and equivalents at quarter-end were 51.7m PLN, with total assets at 109.7m PLN and equity at 73.7m PLN.

• Net cash outflow from operations was 10.5m PLN; investing outflow was 8.5m PLN; financing inflow was 4.8m PLN.

Outlook and guidance

• Plans to start phase II clinical trial for pre-symptomatic type 1 diabetes (PreTreg) in 2024, with patient recruitment expected to begin before year-end.

• Strategic focus on securing pharma partnerships and additional grant funding to support ongoing and future clinical programs.

• Sufficient liquidity for planned activities, but future progress depends on successful grant applications and partnership deals.